Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693606 | 1.00 | LMNA (0.50) | LMNATDP1ALDH1A1CYP3A4HTR6 | |
| SCHEMBL13351700 | 0.85 | MAPT (0.41) | LMNATDP1ALDH1A1CYP3A4HTR6 | |
| SCHEMBL439716 | 0.83 | LMNA (0.59) | LMNATDP1ALDH1A1CYP3A4HTR6 | |
| SCHEMBL11462527 | 0.82 | PIM1 (0.40) | LMNATDP1ALDH1A1CYP3A4HTR6 | |
| SCHEMBL8788979 | 0.81 | ALOX5AP (0.38) | LMNATDP1ALDH1A1CYP3A4HTR6 | |
| SCHEMBL6401649 | 0.79 | ALDH1A1 (0.53) | LMNAALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL11834614 | 0.77 | ALDH1A1 (0.46) | LMNAALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL13351194 | 0.77 | NOS3 (0.48) | LMNATDP1ALDH1A1RAB9AALOX5AP | |
| SCHEMBL8198679 | 0.77 | PDE2A (0.52) | LMNAALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL13068145 | 0.76 | ALDH1A1 (0.41) | LMNATDP1ALDH1A1CYP3A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209435-B | Method for preparing 2, 6-dimethoxy-4-aminopyrimidine through micro-channel | 浙江海昇药业股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-120114996-A | Composite nanofiltration membrane with high permeability and pollution resistance as well as preparation method and application thereof | 同济大学 | 2025-06-10 | — | — | CN | claimed |
| CN-117586194-A | Preparation method of 4-amino-2, 6-dimethoxy pyrimidine | 苏州昊帆生物股份有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117209435-A | Method for preparing 2, 6-dimethoxy-4-aminopyrimidine through micro-channel | 浙江海昇药业股份有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-114014815-B | Preparation method of environment-friendly 4-amino-2, 6-dimethoxy pyrimidine | 浙江科技学院 | 2023-05-30 | — | — | CN | claimed |
| CN-112279888-B | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-09-13 | — | — | CN | claimed |
| CN-110981816-B | Synthesis method of 4-amino-2, 6-dimethoxypyrimidine | 天和药业股份有限公司 | 2022-07-05 | — | — | CN | claimed |
| CN-114014815-A | Preparation method of environment-friendly 4-amino-2, 6-dimethoxypyrimidine | 浙江科技学院 | 2022-02-08 | — | — | CN | claimed |
| CN-109232441-B | Preparation method of 4-amino-2, 6-dimethoxypyrimidine | 南京工业大学 | 2021-08-24 | — | — | CN | claimed |
| CN-112279888-A | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-29 | — | — | CN | claimed |
| EP-1854487-A2 | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | claimed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | LMNA 4249/4885TDP1 1463/4885ALDH1A1 253/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | LMNA 2005/4885TDP1 649/4885ALDH1A1 74/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | LMNA 3468/4885TDP1 1653/4885ALDH1A1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.